亿帆医药: 2025年半年度财务报告

Financial Overview - The total assets of Yifan Pharmaceutical Co., Ltd. increased from CNY 12,285,788,088.75 at the beginning of the period to CNY 12,674,139,895.70 at the end, representing a growth of approximately 3.17% [1][2] - Total liabilities rose from CNY 3,858,992,750.77 to CNY 4,017,412,350.66, indicating an increase of about 4.1% [2][3] - The total equity increased from CNY 8,426,795,337.98 to CNY 8,656,727,545.04, reflecting a growth of approximately 2.72% [2][3] Income Statement Highlights - The total operating revenue for the first half of 2025 was CNY 2,635,110,083.18, slightly up from CNY 2,632,089,783.35 in the same period of 2024 [3][4] - Total operating costs decreased from CNY 2,363,162,281.95 to CNY 2,316,453,207.97, showing a reduction of about 1.98% [4] - Net profit for the first half of 2025 was CNY 284,158,135.82, compared to CNY 212,445,979.23 in the first half of 2024, marking an increase of approximately 33.8% [4][5] Cash Flow Analysis - Net cash flow from operating activities improved significantly, rising from CNY 143,774,218.95 in the first half of 2024 to CNY 286,097,071.23 in the first half of 2025 [5] - Cash flow from investing activities showed a net outflow of CNY 159,041,410.09, compared to a larger outflow of CNY 195,466,241.92 in the previous year [5] - Cash flow from financing activities resulted in a net outflow of CNY 147,413,242.53, contrasting with a net inflow of CNY 207,793,148.58 in the first half of 2024 [5] Balance Sheet Insights - Current assets totaled CNY 3,967,724,843.29 at the end of the period, up from CNY 3,778,271,166.02 at the beginning, indicating a growth of approximately 5.03% [1][2] - Non-current assets increased from CNY 8,507,516,922.73 to CNY 8,706,415,052.41, reflecting a growth of about 2.34% [1][2] - The company's cash and cash equivalents decreased from CNY 889,388,507.75 to CNY 785,909,109.30, a decline of approximately 11.6% [1][2]